美国多发性骨髓瘤随机试验对照组质量系统评价
该系统评价检索了2010至2020年间在美国启动入组的多发性骨髓瘤随机对照试验,评估其对照组方案质量。49项试验中,7项(14%)在已有更优方案发表后仍开始入组劣质对照组,9项(18%)在研究入组期间出现劣质证据后继续入组。16项涉及劣质对照组的试验中12项已发表,其中9项(75%)与先前证明对照组劣质的研究存在研究者重叠。
要点
- 14%的试验在更优方案已发表后仍启动劣质对照组入组。
- 18%的试验在研究期间出现劣质证据后继续入组。
- 劣质对照组试验多与先前证明其劣质的研究者重叠,需加强审查。
核心结论
- 多发性骨髓瘤随机试验中劣质对照组问题存在,需加强对对照组质量的审查。
研究设计与样本
- 系统评价,检索PubMed、Embase、Cochrane Controlled Register of Trials和ClinicalTrials.gov,纳入2010年1月1日至2020年6月30日期间在美国启动入组的多发性骨髓瘤随机对照试验,共49项。
主要发现
- 49项试验中7项(14%)在已有更优方案发表后仍开始入组劣质对照组。
- 49项试验中9项(18%)在研究入组期间出现劣质证据后继续入组亚标准对照组。
- 从首次入组患者到出现对照组劣质新数据的中位时间为13个月(IQR 8-29个月)。
- 16项涉及劣质对照组的试验中12项(75%)已发表,其中9项(75%)与先前证明对照组劣质的研究存在研究者重叠。
关键数值与推荐
- 对照组方案劣质定义为:在入组前已有先前随机对照试验显示某方案较对照组改善无进展生存期。
临床怎么用
- 提示血液科医生在设计或参与多发性骨髓瘤随机试验时,应审查对照组方案是否已被更优方案取代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To our knowledge, no study has evaluated the quality of control groups in randomised controlled trials of multiple myeloma. We aimed to do a systematic review of randomised controlled trials of multiple myeloma to ascertain the quality of the control groups used. PubMed (MEDLINE), Embase, Cochrane Controlled Register of Trials, and CinicalTrials.gov were searched for articles of randomised controlled trials of multiple myeloma based in the USA that initiated participant enrolment between Jan 1, 2010, and June 30, 2020. A control group regimen was considered to be inferior if a previous randomised controlled trial had shown an improved progression-free survival versus the control group before enrolment. Of 49 identified randomised controlled trials, seven (14%) began enrolling patients into inferior control groups after an existing superior regimen to the control had already been published. Nine (18%) of the 49 trials continued enrolment on substandard control groups after data emerged during the study enrolment period. The median time that newer data emerged regarding inferiority of the control group from the time a trial first enrolled a patient was 13 months (IQR 8-29 months). 12 (75%) of these 16 randomised controlled trials are published, and nine (75%) of the 12 published trials had overlapping investigators with trials that had previously shown the inferiority of the control group being used. Greater scrutiny on the quality of control groups in randomised controlled trials of multiple myeloma is needed.
引用
- Mohyuddin GR, Koehn K, Sborov D, et al. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol. 2021. PMID: 33770485. doi:10.1016/S2352-3026(21)00024-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。